Terms: = Kidney tumors AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
125 results:
1. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
Nakayama Y; Enomoto D; Yamamoto K; Takara K
Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
[TBL] [Abstract] [Full Text] [Related]
2. MicroRNA-143-3p Inhibits Wilms' Tumor Cell Growth By Targeting the Ras/Raf/MEK/ERK Pathway.
Zhang L; Shao W
Altern Ther Health Med; 2023 Mar; 29(2):140-147. PubMed ID: 36455140
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological features and diagnosis of pericytic tumors of the kidney].
He YL; Zou YW; Hu YJ; Wu J; Zhang W; Yu WJ; Li YJ; Jiang YX
Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):987-992. PubMed ID: 36207911
[No Abstract] [Full Text] [Related]
4. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.
Sahu DK; Singh N; Das M; Rawat J; Gupta DK
Pediatr Surg Int; 2022 Nov; 38(11):1601-1617. PubMed ID: 36107237
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Analysis of Large-Scale Transcriptomes from Multiple Cancer Types.
Nong B; Guo M; Wang W; Songyang Z; Xiong Y
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946814
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
Grahn A; Eisfeldt J; Malm C; Foroughi Asl H; Jaremko G; Tham E; Brehmer M
BJU Int; 2022 Jul; 130(1):92-101. PubMed ID: 34375486
[TBL] [Abstract] [Full Text] [Related]
8. Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patient with Squamous Cell Carcinoma of the Lung.
Martinez de la Cruz P; Shabaka A; Mielgo-Rubio X; Guerrero-Marquez C; Gimenez-Moyano S; Fernandez-Juarez G
Am J Med Sci; 2021 Jul; 362(1):99-102. PubMed ID: 33872582
[TBL] [Abstract] [Full Text] [Related]
9. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
10. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
Sfakianos JP; Gul Z; Shariat SF; Matin SF; Daneshmand S; Plimack E; Lerner S; Roupret M; Pal S
Eur Urol Oncol; 2021 Apr; 4(2):170-179. PubMed ID: 33386276
[TBL] [Abstract] [Full Text] [Related]
11. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic k-ras.
Volonte D; Sedorovitz M; Cespedes VE; Beecher ML; Galbiati F
J Biol Chem; 2021; 296():100242. PubMed ID: 33380422
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract] [Full Text] [Related]
13. Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas.
Bertz S; Ensser A; Stoehr R; Eckstein M; Apel H; Mayr D; Buettner-Herold M; Gaisa NT; Compérat E; Wullich B; Hartmann A; Knöll A
Mod Pathol; 2020 Jul; 33(7):1433-1442. PubMed ID: 32047230
[TBL] [Abstract] [Full Text] [Related]
14. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing hras stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
15. A Peptide Probe Enables Photoacoustic-Guided Imaging and Drug Delivery to Lung tumors in
Jung H; Park S; Gunassekaran GR; Jeon M; Cho YE; Baek MC; Park JY; Shim G; Oh YK; Kim IS; Kim C; Lee B
Cancer Res; 2019 Aug; 79(16):4271-4282. PubMed ID: 31243044
[TBL] [Abstract] [Full Text] [Related]
16. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363
[TBL] [Abstract] [Full Text] [Related]
17. Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of k-ras Networks of Renal Cell Cancer Cells In Vitro and In Vivo.
Takai T; Tsujino T; Yoshikawa Y; Inamoto T; Sugito N; Kuranaga Y; Heishima K; Soga T; Hayashi K; Miyata K; Kataoka K; Azuma H; Akao Y
Mol Ther; 2019 May; 27(5):1017-1027. PubMed ID: 30930112
[TBL] [Abstract] [Full Text] [Related]
18. Formylated honokiol analogs showed antitumor activity against lung carcinoma.
Deng S; Zhang C; Yang L; Ma L
Anticancer Drugs; 2019 Sep; 30(8):795-802. PubMed ID: 30807551
[TBL] [Abstract] [Full Text] [Related]
19. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.
Tan L; Cho KJ; Neupane P; Capon RJ; Hancock JF
J Biol Chem; 2018 Aug; 293(35):13696-13706. PubMed ID: 29970615
[TBL] [Abstract] [Full Text] [Related]
20. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract] [Full Text] [Related]
[Next]
